Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
J Autoimmun. 2010 Nov;35(3):192-8. doi: 10.1016/j.jaut.2010.06.007. Epub 2010 Jul 23.
A major emphasis of our studies has been on developing a better understanding of how and why the skin serves as a target for immune reactions as well as how the skin evades becoming a target for destruction. For these studies we developed transgenic mice that express a membrane-tethered form of a model self antigen, chicken ovalbumin (mOVA), under the control of a keratin 14 (K14) promoter. K14-mOVA transgenic mice that express OVA mRNA and protein in the epithelia have been assessed for their immune responsiveness to OVA and are being used as targets for T cells obtained from OT-1 transgenic mice whose CD8+ T cells carry a Vα2/Vβ5-transgenic T cell receptor with specificity for the OVA(257-264)-peptides (OVAp) in association with class I MHC antigens. Some of the K14-mOVA transgenic mice develop a graft-versus-host-like disease (GvHD) when the OT-1 cells are injected while others appear to be tolerant to the OT-1 cells. We found that γc cytokines, especially IL-15, determine whether autoimmunity or tolerance ensues in K14-mOVA Tg mice. We also developed transgenic mice that express soluble OVA under the control of a K14 promoter (K14-sOVA) that die within 5-8 days after adoptive transfer of OT-1 cells and identified these mice as a model for more acute GvHD-like reactions. Spontaneous autoimmunity occurs when these K14-sOVA mice are crossed with the OT-I mice. In contrast, we found that preventive or therapeutic OVAp injections induced a dose-dependent increase in survival. In this review the characterization of 5 strains of K14-OVATg mice and underlying mechanisms involved in autoimmune reactions in these Tg mice are discussed. We also describe a strategy to break tolerance and describe how the autoimmunity can be obviated using OVAp. Finally, a historical overview of using transgenic mice to assess the mechanisms of tolerance is also provided.
我们的研究重点主要在于深入了解皮肤为何以及如何成为免疫反应的靶标,以及皮肤为何能够避免成为被破坏的靶标。为此,我们构建了一种转基因小鼠,该小鼠在角蛋白 14(K14)启动子的控制下表达一种膜结合形式的模型自身抗原鸡卵清蛋白(mOVA)。在表皮中表达 OVA mRNA 和蛋白的 K14-mOVA 转基因小鼠已被评估其对 OVA 的免疫反应性,并被用作 OT-1 转基因小鼠 T 细胞的靶标,OT-1 转基因小鼠的 CD8+T 细胞携带对与 I 类 MHC 抗原结合的 OVA(257-264)肽(OVAp)具有特异性的 Vα2/Vβ5-转基因 T 细胞受体。当注射 OT-1 细胞时,一些 K14-mOVA 转基因小鼠会发展出移植物抗宿主病(GvHD)样疾病,而另一些则对 OT-1 细胞表现出耐受。我们发现,γc 细胞因子,尤其是 IL-15,决定了 K14-mOVA Tg 小鼠是发生自身免疫还是耐受。我们还构建了一种在 K14 启动子控制下表达可溶性 OVA 的转基因小鼠(K14-sOVA),在接受 OT-1 细胞过继转移后 5-8 天内死亡,并将这些小鼠鉴定为更急性 GvHD 样反应的模型。当这些 K14-sOVA 小鼠与 OT-1 小鼠杂交时,会自发发生自身免疫。相比之下,我们发现预防性或治疗性 OVAp 注射会导致生存率呈剂量依赖性增加。在这篇综述中,我们讨论了 5 种 K14-OVATg 小鼠的特征以及这些 Tg 小鼠中自身免疫反应的潜在机制。我们还描述了一种打破耐受的策略,并描述了如何使用 OVAp 避免自身免疫。最后,还提供了使用转基因小鼠评估耐受机制的历史概述。